Latest Breaking News On - Hans vitzthum - Page 1 : comparemela.com

JonesTrading welcomes Hans Vitzthum as Managing Director, Business Development

JonesTrading welcomes Hans Vitzthum as Managing Director, Business Development
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Alan hillHans vitzthumResearch market intelligenceBusiness developmentJones trading institutional servicesManaging directorLifesci partnersChief operating officerDerivatives tradingOutsourced tradingElectronic tradingCapital marketsPrime servicesPrivate markets tradingTrading institutional

Foghorn Therapeutics Announces CFO Departure

CAMBRIDGE, Mass., Jan. 03, 2024 Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene.

United kingdomGreg dearbornAllan reineHans vitzthumKarin hellsvikAdrian gottschalkMichael lampeExchange commissionFoghorn therapeutics incTherapeutics incCompany annual report on formChief financial officerChief executive officerGene trafficAnnual reportFoghorn therapeutics

Foghorn Therapeutics Announces CFO Departure

Foghorn Therapeutics Announces CFO Departure
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomMichael lampeKarin hellsvikAdrian gottschalkGreg dearbornAllan reineHans vitzthumExchange commissionFoghorn therapeutics incCompany annual report on formTherapeutics incChief financial officerChief executive officerGene trafficAnnual reportFoghorn therapeutics

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Hans vitzthumSarah kielyRobert stanislaroEli lillyAllen overyExchange commissionAnnounces transaction completedAcquire sepofarsenUltevursen ophthalmicUsher syndromeChief executive officer

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Dec. 01, 2023 Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene.

United statesUnited kingdomSan diegoCourtneyd dinardoHans vitzthumMichael lampeGreg dearbornKarin hellsvikCompany annual report on formUniversity of texas md anderson cancer centerExchange commissionTherapeutics incAmerican society of hematologyFoghorn therapeutics incAmerican societyAnnual meeting